Alternative splicing in colon, bladder, and prostate cancer identified by exon array analysis.

Area of Science:

• Molecular Biology
• Genomics
• Cancer Research

Background:

• Alternative splicing significantly expands proteome diversity.
• Dysregulated alternative splicing is implicated in cancer development and progression.
• Understanding tissue- and tumor-specific splicing is crucial for identifying cancer biomarkers and therapeutic targets.

Purpose of the Study:

• To identify and validate tissue- and tumor-specific alternative splicing events in colon, urinary bladder, and prostate tissues.
• To assess the diagnostic and prognostic potential of identified splicing alterations in cancer.
• To explore the functional implications of cancer-specific splice variants.

Main Methods:

• Whole-genome exon expression analysis using GeneChip Human Exon 1.0 ST Array on 102 normal and cancer tissue samples.
• RT-PCR validation of candidate alternative splicing events.
• In silico prediction of protein function for identified splice variants.

Main Results:

• Identified 2069 candidate alternative splicing events between normal tissues.
• Validated seven genes with tumor-specific splice variants (ACTN1, CALD1, COL6A3, LRRFIP2, PIK4CB, TPM1, VCL).
• Validated alterations clearly separated normal from cancer samples and, in some cases, different tumor stages.
• A subset of alterations (ACTN1, CALD1, VCL) was common across all three cancer types.

Conclusions:

• Identified and validated alternative splicing events in normal and cancerous colon, bladder, and prostate tissues.
• Discovered tumor-specific splicing alterations with potential diagnostic and prognostic value.
• Cancer-specific splice variants may encode proteins with altered functions, representing novel therapeutic targets.